AAPL   381.51 (-0.32%)
MSFT   213.07 (-0.58%)
GOOGL   1,523.57 (+0.32%)
AMZN   3,184.58 (+0.06%)
BABA   259.71 (-0.71%)
TSLA   1,492.50 (+7.04%)
ACB   11.92 (+1.19%)
GILD   76.15 (+1.93%)
BAC   23.90 (+4.92%)
NFLX   551.36 (+8.59%)
AAPL   381.51 (-0.32%)
MSFT   213.07 (-0.58%)
GOOGL   1,523.57 (+0.32%)
AMZN   3,184.58 (+0.06%)
BABA   259.71 (-0.71%)
TSLA   1,492.50 (+7.04%)
ACB   11.92 (+1.19%)
GILD   76.15 (+1.93%)
BAC   23.90 (+4.92%)
NFLX   551.36 (+8.59%)
AAPL   381.51 (-0.32%)
MSFT   213.07 (-0.58%)
GOOGL   1,523.57 (+0.32%)
AMZN   3,184.58 (+0.06%)
BABA   259.71 (-0.71%)
TSLA   1,492.50 (+7.04%)
ACB   11.92 (+1.19%)
GILD   76.15 (+1.93%)
BAC   23.90 (+4.92%)
NFLX   551.36 (+8.59%)
AAPL   381.51 (-0.32%)
MSFT   213.07 (-0.58%)
GOOGL   1,523.57 (+0.32%)
AMZN   3,184.58 (+0.06%)
BABA   259.71 (-0.71%)
TSLA   1,492.50 (+7.04%)
ACB   11.92 (+1.19%)
GILD   76.15 (+1.93%)
BAC   23.90 (+4.92%)
NFLX   551.36 (+8.59%)
Log in

LON:RENEReNeuron Group Share Price, Forecast & News

GBX 142.50
+2.50 (+1.79 %)
(As of 07/10/2020 02:29 PM ET)
Add
Compare
Today's Range
142.50
Now: GBX 142.50
145.06
50-Day Range
125
MA: GBX 139.16
151
52-Week Range
71
Now: GBX 142.50
297.50
Volume14,977 shs
Average Volume28,700 shs
Market Capitalization£45.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Read More
ReNeuron Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-38198400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£6.39 million
Cash FlowGBX 66.10 per share
Book ValueGBX 63.50 per share

Profitability

Miscellaneous

Employees62
Market Cap£45.36 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group (LON:RENE) Frequently Asked Questions

How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)?

ReNeuron Group's stock was trading at GBX 106 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RENE shares have increased by 34.4% and is now trading at GBX 142.50. View which stocks have been most impacted by Coronavirus.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) released its quarterly earnings results on Friday, December, 6th. The company reported ($12.30) earnings per share for the quarter, topping analysts' consensus estimates of ($16.30) by $4.00. View ReNeuron Group's earnings history.

Has ReNeuron Group been receiving favorable news coverage?

Media coverage about RENE stock has trended somewhat positive on Friday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ReNeuron Group earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 142.50.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £45.36 million and generates £6.39 million in revenue each year. ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.